Johnson & Johnson stock kpis
Want to see JNJ full AI Analyst Report?
Revenue by Segment
In Q3 2026, Johnson & Johnson reported revenue by segment of $16.76B (Pharmaceutical) and $8.64B (Medtech).
Breaks revenue down by business line—primarily pharmaceuticals and medical devices for J&J—revealing which segments deliver the most sales and profits. Makes it easier to judge dependence on blockbuster drugs or device portfolios, see where margins are strongest, and assess how R&D or regulatory risks in a single segment could affect overall performance.
Consumer Health falls to zero from mid‑2023 onward because J&J completed the spin‑off/divestiture, leaving Pharmaceuticals and MedTech as the core drivers. Pharmaceuticals show clear acceleration fueled by multiple high‑growth launches that largely offset STELARA’s steep decline, underpinning management’s raised FY26 sales/EPS guidance. MedTech growth is steadier but faces selective cardiovascular/Abiomed and China inventory headwinds—key risks to near‑term upside; watch STELARA’s trajectory, procedural recovery, and upcoming pipeline/M&A catalysts for sustainability.
JNJ Revenue by Segment
| Period | Pharmaceutical | Medtech | Consumer Health |
|---|---|---|---|
| Q3 2026Sep 30, 2026 | $16.76B | $8.64B | $0.00 |
| Q2 2026Jun 30, 2026 | $16.38B | $8.93B | $0.00 |
| Q1 2026Mar 31, 2026 | $15.43B | $8.64B | $0.00 |
| Q4 2025Dec 31, 2025 | $15.76B | $8.80B | $0.00 |
| Q3 2025Sep 30, 2025 | $15.56B | $8.43B | $0.00 |
| Q2 2025Jun 30, 2025 | $15.20B | $8.54B | $0.00 |
| Q1 2025Mar 31, 2025 | $13.87B | $8.02B | $0.00 |
| Q4 2024Dec 31, 2024 | $14.33B | $8.19B | $0.00 |
| Q3 2024Sep 30, 2024 | $14.58B | $7.89B | $0.00 |
| Q2 2024Jun 30, 2024 | $14.49B | $7.96B | $0.00 |
| Q1 2024Mar 31, 2024 | $13.56B | $7.82B | $0.00 |
| Q4 2023Dec 31, 2023 | $13.72B | $7.67B | $0.00 |
| Q3 2023Sep 30, 2023 | $13.89B | $7.46B | $0.00 |
| Q2 2023Jun 30, 2023 | $13.73B | $7.79B | $4.01B |
| Q1 2023Mar 31, 2023 | $13.41B | $7.48B | $3.85B |
| Q4 2022Dec 31, 2022 | $13.16B | $6.78B | $3.77B |
| Q3 2022Sep 30, 2022 | $13.21B | $6.78B | $3.79B |
| Q2 2022Jun 30, 2022 | $13.32B | $6.90B | $3.81B |
| Q1 2022Mar 31, 2022 | $12.87B | $6.97B | $3.59B |
| Q4 2021Dec 31, 2021 | $14.22B | $6.86B | $3.73B |
| Q3 2021Sep 30, 2021 | $12.88B | $6.64B | $3.81B |
| Q2 2021Jun 30, 2021 | $12.60B | $6.98B | $3.73B |
| Q1 2021Mar 31, 2021 | $12.20B | $6.58B | $3.54B |
| Q4 2020Dec 31, 2020 | $12.27B | $6.59B | $3.62B |
| Q3 2020Sep 30, 2020 | $11.42B | $6.15B | $3.51B |
| Q2 2020Jun 30, 2020 | $10.75B | $4.29B | $3.30B |
| Q1 2020Mar 31, 2020 | $11.13B | $5.93B | $3.63B |
| Q4 2019Dec 31, 2019 | $10.55B | $6.63B | $3.57B |
| Q3 2019Sep 30, 2019 | $10.88B | $6.38B | $3.47B |
| Q2 2019Jun 30, 2019 | $10.53B | $6.49B | $3.54B |
| Q1 2019Mar 31, 2019 | $10.24B | $6.46B | $3.32B |
| Q4 2018Dec 31, 2018 | $10.19B | $6.67B | $3.54B |
| Q3 2018Sep 30, 2018 | $10.35B | $6.59B | $3.42B |
| Q2 2018Jun 30, 2018 | $10.35B | $6.97B | $3.50B |
| Q1 2018Mar 31, 2018 | $9.84B | $6.77B | $3.40B |
| Q4 2017Dec 31, 2017 | $9.68B | $6.97B | $3.54B |
| Q3 2017Sep 30, 2017 | $9.70B | $6.60B | $3.36B |
| Q2 2017Jun 30, 2017 | $8.63B | $6.73B | $3.48B |
| Q1 2017Mar 31, 2017 | $8.24B | $6.29B | $3.23B |

